Peptide

GHRH (1-44)

Also known as

Somatorelin · Growth hormone–releasing hormone (1-44) · hGHRH(1-44) · hGHRH(1-44)NH2 · GHRH-1,44-amide · GRF (1-44) · Growth hormone–releasing factor (1-44) · Somatocrinin (endogenous form discussions) · GHRH 1-44 amide · somatotropin releasing hormone (1-44)amide · Full-length GHRH

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	Full-length, 44-amino-acid growth-hormone-releasing hormone, also called somatorelin; it signals the pituitary to release GH.
Analog distinction	Sermorelin, tesamorelin, Mod GRF and CJC products are different peptides. Their doses and experiences do not establish native 1-44 results.

Notes

A signal to release growth hormone. The 44-amino-acid human peptide, commonly GHRH(1-44)-NH2 or somatorelin, stimulates pituitary GH release. IGF-1 is a downstream response. This differs from injecting GH itself; it is systemic, rather than a local repair or spot-fat treatment. Paltusotine trial: somatorelin challenge identity (Official context · Accessed 2026-09-30)

The name does not identify every analog. Sermorelin is the 1-29 fragment; tesamorelin is modified full-length GHRH; Mod GRF and CJC products have other modifications. MESO discussion favors stabilized analogs because injected native peptide degrades quickly. Oral MK-677 acts through the ghrelin pathway and is not GHRH. Native GHRH versus modified analogs; bedtime disagreement (Community opinion · Accessed 2026-09-30)

GHRH (1-44) is the full-length growth-hormone release signal behind several familiar peptide analogs. Biohackers discuss it for recovery, sleep and body composition, but practical reports often describe a different GHRH peptide. Native 1-44 has little isolated lifestyle experience; borrowed analog numbers need careful reading.

Source context — Paltusotine trial: somatorelin challenge identity: Methods paragraph inspected, not full outcome review. PMC browser page returned reCAPTCHA; Europe PMC HTML failed. Diagnostic challenge cannot supply native lifestyle SC dose or onset.

Source context — Native GHRH versus modified analogs; bedtime disagreement: Translated community educational repost from an unnamed earlier forum, not an independent native 1-44 experiment. HGH-fragment sleep/night-sweat reports in nearby posts are a different compound and excluded.

What people notice

What people seek	Better recovery, sleep and body composition; most practical sleep/recovery reports in this record concern sermorelin or CJC combinations.
Native experience	Isolated native 1-44 lifestyle outcomes remain unclear. A GH pulse does not establish a visible improvement, and warmth or a good night's sleep does not measure a hormone change.

Notes

Recovery, sleep and body composition. Community interest includes lean mass, easier recovery, deeper sleep and anti-aging goals. The original account places much of the sleep/recovery experience with bedtime sermorelin or CJC combinations. That makes native 1-44 a poor identity to attach those results to.

A GH pulse is not a visible transformation. The appeal is stimulating endogenous GH while retaining feedback. Forum proponents frame this as more physiological, but feedback does not prove safety. Training, protein, calories and sleep complicate body-composition reports; isolated native 1-44 outcomes remain unclear.

No reliable native 1-44 onset window. The original account includes little distinctive feel in the first week and sleep/recovery stories around weeks 3–4, without isolated logs. Those intervals describe uncertain experiences, not measured GH onset. Neither warmth nor a good night proves a hormone change.

Doses people talk about

Borrowed bedtime amounts	200–300 mcg under the skin at bedtime, within a broader 100–500 mcg nightly sermorelin band, is analog talk rather than an established native 1-44 amount.
Generic GHRH/GHRP chart	100–300 mcg GHRH plus 100–200 mcg GHRP per administration, under the skin 1–4 times daily, is a circulated class chart; it does not establish native 1-44 exposure.
Native human research	Separate studies used 1 or 2 mg/day continuous subcutaneous infusion for 14 days, or 1 mg under the skin twice daily for three months. These are research settings.

Notes

200–300 mcg at bedtime: borrowed SC talk. The original account retains this subcutaneous pattern borrowed from sermorelin, plus a broader 100–500 mcg SC nightly sermorelin comparison band. These are amounts per administration for another peptide, not an established native 1-44 dose or a prescription.

100–300 mcg per GHRH administration: generic forum chart. Steroidology pairs this with 100–200 mcg GHRP, SC, one to four times daily, 5–7 days weekly. It does not establish native 1-44 exposure. Each component has its own amount; a blend total cannot substitute for either. GHRH and GHRP overview with follow-up discussion (Community guide · Accessed 2026-09-30) · Overview of HGH Secretagogues (Community discussion · Accessed 2026-09-30)

Milligram research differs from microgram forum borrowing. Corpas 1993 used 1 or 2 mg/day continuous SC infusion for 14 days, with 14 days between treatments, raising GH and IGF-1. A diagnostic trial used 50 mcg somatorelin IV with serial blood draws. Neither supplies a lifestyle regimen. Corpas et al. 1993: continuous SC GHRH 1-44 (Official context · Accessed 2026-09-30) · Paltusotine trial: somatorelin challenge identity (Official context · Accessed 2026-09-30)

A small study had benefits, unchanged measures and symptoms. Ten postmenopausal women received 1 mg SC twice daily, 2 mg/day total, for three months. GH rose about 98%, IGF-1 71% from week two, visceral fat fell 16%, and body water rose 14%; walking/stairs improved, but strength and lean mass did not. Seven had local reactions; two reported weight gain/joint aches, one carpal-tunnel symptoms. No control group limits interpretation. Veldhuis et al. 2005: full-length GHRH in ten postmenopausal volunteers (Official context · Accessed 2026-09-30)

Source context — GHRH and GHRP overview with follow-up discussion: Internet compilation, not native 1-44 self-use or verified pharmacokinetics; unspecified route for half-life. Says 'studies' without supporting citations. Replies concern analogs. Safety assurances are not adopted.

Source context — Overview of HGH Secretagogues: Analog discussion, not native 1-44 use. Some advice is overconfident or factually loose; all-GHRHs 100 mcg and benign-peptide framing rejected. Partial replies/deleted accounts limit follow-up.

Source context — Corpas et al. 1993: continuous SC GHRH 1-44: Abstract-only review; older male research population and pump delivery, not a community injection cycle.

Source context — Veldhuis et al. 2005: full-length GHRH in ten postmenopausal volunteers: Author-uploaded article text inspected, not merely the platform-generated author metadata. Small uncontrolled before/after study; abstract's no-systemic-AE wording omits symptoms recorded in full text.

Half-life, onset & duration

Felt onset	No reliable native 1-44 window. Older little-feel first-week and weeks-3–4 sleep/recovery stories lack isolated native logs.
Felt duration	Not established for native 1-44. Generic pulse-length claims and analog-based days-to-weeks fade-out expectations measure different things.
Half-life	6.8 minutes for intact 1-44 amide after human IV injection. No subcutaneous half-life is established here; laboratory incubation values describe a different setting.

Notes

A short pulse is different from lasting benefit. Steroidology circulates a less-than-30-minute pulse and 2.5–3-hour spacing rationale. These are class claims, not native 1-44 measured benefit duration. GHRH and GHRP overview with follow-up discussion (Community guide · Accessed 2026-09-30)

After stopping remains uncertain. The original account expects downstream effects to fade over days to weeks, partly borrowing from analog discontinuation. Native washout accounts are thin. Peptide clearance, sleep that night, IGF-1 changes and maintained body composition are different endpoints.

6.8 minutes IV; 17 and 63 minutes in a laboratory. Frohman 1986 measured intact 1-44 amide after human intravenous injection: 6.8 minutes. Incubating it in human plasma in a laboratory gave 17 minutes for intact peptide, but 63 minutes when the test also detected inactive fragments. These measure different material in different settings, not half-lives for injection beneath the skin. Frohman et al. 1986: intact peptide and assay differences (Official context · Accessed 2026-09-30)

Source context — Frohman et al. 1986: intact peptide and assay differences: Abstract inspected; no subcutaneous human half-life or subjective-duration measurement. Laboratory incubation is not in-vivo human kinetics.

Cycles people discuss

Analog borrowing	5 nights on, 2 off comes mainly from sermorelin, CJC combinations or tesamorelin discussion; it is not an established native 1-44 cycle.
Other class calendars	A generic forum chart gives 4–8 weeks on, 4 off; an analog user describes at least six months. These conflicting calendars do not settle native use.

Notes

5 nights on, 2 off: analog borrowing. This older community calendar belongs mainly to sermorelin, CJC combinations or tesamorelin. A Reddit tesamorelin-stack reply repeats 5 days on, 2 off; neither establishes a native 1-44 cycle. Overview of HGH Secretagogues (Community discussion · Accessed 2026-09-30)

4–8 weeks on, 4 off: a separate generic claim. Steroidology circulates this GHRH schedule. Its analog user also describes courses of at least six months. Keep those conflicting calendars separate; neither proves long-term tolerability or a need to cycle native 1-44. GHRH and GHRP overview with follow-up discussion (Community guide · Accessed 2026-09-30)

Stacks

GHRH plus GHRP	Ipamorelin, GHRP-2 or GHRP-6 are paired with GHRH agents in class discussion; modern logs rarely identify native 1-44 as the GHRH component.
Usual analog combinations	The saved injection-burden discussion favors Mod GRF with GHRP-2; this is a different peptide combination, not native 1-44 experience.

Notes

GHRH + GHRP dual pathway: Class stack pairs a GHRH agent with a ghrelin-receptor GHRP (ipamorelin preferred for lower hunger/cortisol lore; GHRP-2 and GHRP-6 still discussed) — native 1–44 is rarely the named GHRH half of modern logs. [community]

Injection burden changes choices. A Reddit exchange weighs repeated injections against longer-lived analogs; the author prefers Mod GRF with GHRP-2, while another commenter reports benefits with once-daily use of unspecified peptides. Neither is a native 1-44 log. Older stack talk likewise centers on ipamorelin, GHRP-2 or GHRP-6 paired with analogs. Overview of HGH Secretagogues (Community discussion · Accessed 2026-09-30)

Watch for

GH-axis complaints	Class reports include water retention, joint aches, tingling, headache, glucose concerns and injection reactions; they do not give native 1-44 incidence.
Native study symptoms	The small three-month study recorded local reactions, weight gain/joint aches and carpal-tunnel symptoms; strength and lean mass did not improve.
Identity and sport	Amidation, salt, purity and confusion between 1-40, 1-44 and analogs matter. The saved WADA source prohibits GHRH and analogues at all times.

Notes

Skin reactions and GH-axis symptoms. Older community cautions include redness, itching, swelling, water retention, joint aches, tingling, headache and glucose concerns. These are class reports, not native incidence estimates. Sparse reporting does not establish safety; cancer/IGF-1 concerns are also class-level uncertainty.

Product identity is part of the uncertainty. The original record flags amidation, salt, purity and confusion among 1-40, 1-44 and analogs. A vial name cannot authenticate its contents. Current WADA rules prohibit GHRH and analogues at all times for athletes subject to those rules. WADA 2026 Prohibited List (Official context · Accessed 2026-09-30)

Source context — WADA 2026 Prohibited List: Sport rule context, not general legal classification or a safety finding.

Full notes

What GHRH (1-44) actually is

A signal to release growth hormone. The 44-amino-acid human peptide, commonly GHRH(1-44)-NH2 or somatorelin, stimulates pituitary GH release. IGF-1 is a downstream response. This differs from injecting GH itself; it is systemic, rather than a local repair or spot-fat treatment. Official context Community
The name does not identify every analog. Sermorelin is the 1-29 fragment; tesamorelin is modified full-length GHRH; Mod GRF and CJC products have other modifications. MESO discussion favors stabilized analogs because injected native peptide degrades quickly. Oral MK-677 acts through the ghrelin pathway and is not GHRH. MESO-Rx Français Community

Benefits people seek

Recovery, sleep and body composition. Community interest includes lean mass, easier recovery, deeper sleep and anti-aging goals. The original account places much of the sleep/recovery experience with bedtime sermorelin or CJC combinations. That makes native 1-44 a poor identity to attach those results to. Community
A GH pulse is not a visible transformation. The appeal is stimulating endogenous GH while retaining feedback. Forum proponents frame this as more physiological, but feedback does not prove safety. Training, protein, calories and sleep complicate body-composition reports; isolated native 1-44 outcomes remain unclear. Community Community

Doses discussed

200–300 mcg at bedtime: borrowed SC talk. The original account retains this subcutaneous pattern borrowed from sermorelin, plus a broader 100–500 mcg SC nightly sermorelin comparison band. These are amounts per administration for another peptide, not an established native 1-44 dose or a prescription. Community
100–300 mcg per GHRH administration: generic forum chart. Steroidology pairs this with 100–200 mcg GHRP, SC, one to four times daily, 5–7 days weekly. It does not establish native 1-44 exposure. Each component has its own amount; a blend total cannot substitute for either. Community guide Reddit r/Peptides

Half-life discussed

Under 5–10 minutes: circulated GRF(1-44) claim. Steroidology explicitly lists this estimate, without route or assay. It is an educational repost, not a user measurement; the exact formal IV result is identified separately below. CJC-DAC days-long figures describe another molecule. Community guide Community

When people notice something

No reliable native 1-44 onset window. The original account includes little distinctive feel in the first week and sleep/recovery stories around weeks 3–4, without isolated logs. Those intervals describe uncertain experiences, not measured GH onset. Neither warmth nor a good night proves a hormone change. Community

How long the effect is discussed

A short pulse is different from lasting benefit. Steroidology circulates a less-than-30-minute pulse and 2.5–3-hour spacing rationale. These are class claims, not native 1-44 measured benefit duration. Community guide
After stopping remains uncertain. The original account expects downstream effects to fade over days to weeks, partly borrowing from analog discontinuation. Native washout accounts are thin. Peptide clearance, sleep that night, IGF-1 changes and maintained body composition are different endpoints. Community

Cycles discussed

5 nights on, 2 off: analog borrowing. This older community calendar belongs mainly to sermorelin, CJC combinations or tesamorelin. A Reddit tesamorelin-stack reply repeats 5 days on, 2 off; neither establishes a native 1-44 cycle. Community Reddit r/Peptides
4–8 weeks on, 4 off: a separate generic claim. Steroidology circulates this GHRH schedule. Its analog user also describes courses of at least six months. Keep those conflicting calendars separate; neither proves long-term tolerability or a need to cycle native 1-44. Community guide

What to watch for

Skin reactions and GH-axis symptoms. Older community cautions include redness, itching, swelling, water retention, joint aches, tingling, headache and glucose concerns. These are class reports, not native incidence estimates. Sparse reporting does not establish safety; cancer/IGF-1 concerns are also class-level uncertainty. Community
Product identity is part of the uncertainty. The original record flags amidation, salt, purity and confusion among 1-40, 1-44 and analogs. A vial name cannot authenticate its contents. Current WADA rules prohibit GHRH and analogues at all times for athletes subject to those rules. Community Community Official context

Separate formal context

6.8 minutes IV; 17 and 63 minutes in a laboratory. Frohman 1986 measured intact 1-44 amide after human intravenous injection: 6.8 minutes. Incubating it in human plasma in a laboratory gave 17 minutes for intact peptide, but 63 minutes when the test also detected inactive fragments. These measure different material in different settings, not half-lives for injection beneath the skin. Official context
Milligram research differs from microgram forum borrowing. Corpas 1993 used 1 or 2 mg/day continuous SC infusion for 14 days, with 14 days between treatments, raising GH and IGF-1. A diagnostic trial used 50 mcg somatorelin IV with serial blood draws. Neither supplies a lifestyle regimen. Official context Official context
A small study had benefits, unchanged measures and symptoms. Ten postmenopausal women received 1 mg SC twice daily, 2 mg/day total, for three months. GH rose about 98%, IGF-1 71% from week two, visceral fat fell 16%, and body water rose 14%; walking/stairs improved, but strength and lean mass did not. Seven had local reactions; two reported weight gain/joint aches, one carpal-tunnel symptoms. No control group limits interpretation. Official context
Degradation explains the analog interest. Frohman 1989 describes enzymes cutting and breaking down the peptide. That mechanism does not turn analog doses into native doses or provide a safety assurance. Official context

Community experience and tradeoffs

Injection burden changes choices. A Reddit exchange weighs repeated injections against longer-lived analogs; the author prefers Mod GRF with GHRP-2, while another commenter reports benefits with once-daily use of unspecified peptides. Neither is a native 1-44 log. Older stack talk likewise centers on ipamorelin, GHRP-2 or GHRP-6 paired with analogs. Reddit r/Peptides Community
Bedtime and fasting rules are disputed. The MESO repost promotes bedtime use but includes an objection about interfering with natural secretion. A later Reddit tesamorelin thread disputes fasting versus after-meal dosing by referring to older GHRH studies in different populations. Neither conversation establishes a universal native 1-44 timing rule. MESO-Rx Français Reddit r/Retatrutide
Positive accounts coexist with unwanted reactions. Reddit krgrunst reports hives with ipamorelin/CJC and sermorelin; DustinEwan describes intermittent local itching/redness. Their products are analogs, so these do not establish native 1-44 reactions. The original little-feel account remains relevant without an invented responder rate. Fat-loss debates similarly differ over tesamorelin's molecule versus the population studied. Reddit r/Peptides Community